First Beta Unit of the Aether 1 Bioprinter Ships to the University of Cambridge, Ready to “Absolutely Transform the Entire Bioprinting Market”
About a year ago, a startup called Aether seemed to come right out of the ether, promising a bold new 3D bioprinter with more than 20 swappable extruders. The multipurpose Aether 1 sounded too good to be true, especially coming from a new, unknown company, but it’s already gotten serious interest from a number of universities and research institutions, several of which have signed on to participate in a large-scale research project using Aether 1 beta units.
A few days ago, that project officially began as Aether shipped their first beta unit to the University of Cambridge. Bioengineering professor Dr. Yan Yan Shery Huang, along with her student Elisabeth Gill, will be the first to try out the Aether 1. Dr. Huang specializes in bioengineering, with a particular focus on bioprinting and other novel fabrication techniques – and the Aether 1 certainly meets the criteria for novel fabrication. Aether hopes that the machine will make a valuable contribution to Dr. Huang and Gill’s research, but the pair will also assist in the printer’s further development by testing it and offering feedback.
“Since this is the very first beta unit, it’s a bit ‘raw’ and there are many improvements that need to be made, and problems that remain to be solved,” Aether states. “As our first beta users, they will likely discover new issues, both large and small, that we aren’t aware of yet.”
The Aether 1, in addition to its bioprinting capabilities, offers multiple other fabrication options from food printing to electronics printing to laser engraving. According to Aether, the printer’s major core functions, including options for FDM/FFF 3D printing, syringe extrusion, droplet jetting, and laser engraving, are in place and have been performing well in tests, as are the machine’s four primary automation features: machine vision-based fully automatic air pressure calibration; automatic true mechanical stage leveling; dual automatic multi-function cleaning stations; and automatic offset calibration.
The Aether 1’s automated features are one of its key selling points, in addition to its multitudinous fabrication capabilities. Bioprinting is no simple task, but according to Aether, they’ve made it a lot easier by automating the most complicated and time-consuming parts of the process, ensuring accuracy by replacing “eyeball approximations” with precise sensors and algorithms.
The printer is also remarkably inexpensive at $9,000. Other high-end bioprinters can run as expensive as $250,000 or more, while offering fewer extruders and fabrication methods, and “maybe 1 automation method,” as the company’s CEO tells us. He continues, noting that more comparably priced ($10K-$20K) bioprinters offer even fewer extruders and fabrication methods, with zero automation.
“Aether 1 has up to 24 extruders, 8 fabrication methods, and 4 never-before-seen, totally revolutionary automation features. It crushes the high-end, but it’s priced on the low-end,” Aether CEO Ryan Franks tells 3DPrint.com. “Aether’s shipment to Cambridge marks the beginning of a radical paradigm shift for what researchers can do with a bioprinter, which will soon absolutely transform the entire bioprinting market.”
As the Aether 1 shipped out to Cambridge, the company was in transit as well, moving from their cramped 250-square-foot office to a 2,600-square-foot office in San Francisco’s South of Market (SoMa) district. A larger space has become increasingly necessary as Aether adds to their team; recently they expanded their engineering team and are looking to further increase its size.
Production will be scaling up as well; Aether hopes to ship additional beta units out towards the end of the month, with the goal of sending them to all of the institutions that have signed on for research collaborations as soon as possible. Discuss in the Aether forum at 3DPB.com.
You May Also Like
Ricoh to Buy 34.5 Percent of Bioprinting Company Elixirgen Scientific
Japan’s Ricoh Company, Ltd. announces further investment in 3D printing—and bioprinting—teaming up with Elixirgen Scientific, Inc. of Baltimore Maryland. Together, they will be focused on creating new products for the...
A Bioprinting World Map
With 109 established bioprinting companies and many entrepreneurs around the world showing interest in the emerging field, it’s just a matter of time before it becomes one of the most...
Interview with Jose Manuel Baena of Regemat 3D and Breca Health Care
This is an interview with Jose Manuel Baena of Regemat 3D and Breca Health Care. These organizations are doing various work in the bio-printing sector as well as the medical device sector.
European Bioprinting Company regenHU is Paving the Way in Therapeutical Bioprinting
Nestled in the Fribourg countryside, amid medieval towns, deep mountain lakes, and Swiss-alpine traditions, bioprinting company regenHU (which stands for regeneration human) is developing some of the most advanced 3D...
View our broad assortment of in house and third party products.